Literature DB >> 20878324

Intensive versus conventional insulin therapy in type 2 diabetes patients undergoing D2 gastrectomy for gastric cancer: a randomized controlled trial.

Shou-Gen Cao1, Jian-An Ren, Bo Shen, Dong Chen, Yan-Bing Zhou, Jie-Shou Li.   

Abstract

BACKGROUND: This study was to compare the effect of intensive insulin therapy (IIT) to conventional insulin therapy (CIT) on postoperative outcomes among type 2 diabetes mellitus (DM) patients who underwent D2 gastrectomy for gastric cancer.
METHODS: We randomly assigned gastric cancer patients with type 2 DM who underwent radical gastrectomy to receive IIT (maintenance of blood glucose at a level between 4.4 and 6.1 mmol/l) with insulin infusion or CIT (maintenance of blood glucose at a level between 10 and 11.1 mmol/l) during the postoperative period.
RESULTS: Of the 179 eligible patients, 92 patients were assigned to receive IIT and 87 patients to receive CIT. Mean blood glucose concentrations were lower in the intensive group (IG) than in the conventional group (CG) (5.5 ± 0.8 vs. 9.9 ± 1.0 mmol/l, P < 0.001). Hypoglycemia occurred in 6 patients (6.5%) in the IG (P = 0.029) versus in 1 patient (1.1%) in the CG. Hospital mortality did not differ significantly between two groups (4.3% vs. 5.7%, P = 0.742). However, IIT significantly reduced morbidity (from 18.4 to 7.6%, P = 0.031). Also, IIT shortened the days to suture removal, postoperative hospital stay, and postoperative duration of antibiotic use. The HOMA-IR score was lower at all time points in IG. Moreover, IIT increased the postoperative HLA-DR expression on monocytes on postoperative days 3 and 5.
CONCLUSIONS: IIT significantly reduced short-term morbidity but not mortality among type 2 DM patients who underwent D2 gastrectomy for gastric cancer. Furthermore, a possible mechanism of suppression of the insulin resistance and improvement of HLA-DR expression may partially explain the benefits of IIT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20878324     DOI: 10.1007/s00268-010-0797-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  31 in total

1.  Validity of HOMA-IR as index of insulin resistance in obesity.

Authors:  Angelika Mohn; Maria Marcovecchio; Francesco Chiarelli
Journal:  J Pediatr       Date:  2006-04       Impact factor: 4.406

2.  [Effects of intensive insulin therapy on insulin resistance and serum proteins after radical gastrectomy].

Authors:  Qing-guang Wang; Lian-fang Lu; Yan-bing Zhou; Shou-gen Cao; Dong-sheng Wang; Liang Lv
Journal:  Zhonghua Wei Chang Wai Ke Za Zhi       Date:  2008-09

3.  Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas.

Authors:  M Emoto; Y Nishizawa; K Maekawa; Y Hiura; H Kanda; T Kawagishi; T Shoji; Y Okuno; H Morii
Journal:  Diabetes Care       Date:  1999-05       Impact factor: 19.112

4.  Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures.

Authors:  A P Furnary; K J Zerr; G L Grunkemeier; A Starr
Journal:  Ann Thorac Surg       Date:  1999-02       Impact factor: 4.330

5.  Surgery-induced insulin resistance in human patients: relation to glucose transport and utilization.

Authors:  A Thorell; J Nygren; M F Hirshman; T Hayashi; K S Nair; E S Horton; L J Goodyear; O Ljungqvist
Journal:  Am J Physiol       Date:  1999-04

6.  Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients.

Authors:  Alexandre Ouattara; Patrick Lecomte; Yannick Le Manach; Marc Landi; Sophie Jacqueminet; Igor Platonov; Nicolas Bonnet; Bruno Riou; Pierre Coriat
Journal:  Anesthesiology       Date:  2005-10       Impact factor: 7.892

7.  Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients.

Authors:  Ilse Vanhorebeek; Rita De Vos; Dieter Mesotten; Pieter J Wouters; Christiane De Wolf-Peeters; Greet Van den Berghe
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

8.  Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events.

Authors:  Harold L Lazar; Stuart R Chipkin; Carmel A Fitzgerald; Yusheng Bao; Howard Cabral; Carl S Apstein
Journal:  Circulation       Date:  2004-03-08       Impact factor: 29.690

9.  Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting.

Authors:  Anthony P Furnary; Guangqiang Gao; Gary L Grunkemeier; YingXing Wu; Kathryn J Zerr; Stephen O Bookin; H Storm Floten; Albert Starr
Journal:  J Thorac Cardiovasc Surg       Date:  2003-05       Impact factor: 5.209

10.  Benefits and risks of tight glucose control in critically ill adults: a meta-analysis.

Authors:  Renda Soylemez Wiener; Daniel C Wiener; Robin J Larson
Journal:  JAMA       Date:  2008-08-27       Impact factor: 56.272

View more
  11 in total

Review 1.  A meta-analysis of fast track surgery for patients with gastric cancer undergoing gastrectomy.

Authors:  S Chen; Z Zou; F Chen; Z Huang; G Li
Journal:  Ann R Coll Surg Engl       Date:  2015-01       Impact factor: 1.891

Review 2.  Glycemic control, mortality, and hypoglycemia in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials.

Authors:  Tomohide Yamada; Nobuhiro Shojima; Hisashi Noma; Toshimasa Yamauchi; Takashi Kadowaki
Journal:  Intensive Care Med       Date:  2016-09-16       Impact factor: 17.440

3.  Intensive versus conventional insulin therapy in nondiabetic patients receiving parenteral nutrition after D2 gastrectomy for gastric cancer: a randomized controlled trial.

Authors:  Shougen Cao; Yanbing Zhou; Dong Chen; Zhaojian Niu; Dongsheng Wang; Liang Lv; Yu Li
Journal:  J Gastrointest Surg       Date:  2011-09-09       Impact factor: 3.452

4.  Intensive Versus Conventional Glycemic Control in Patients with Diabetes During Enteral Nutrition After Gastrectomy.

Authors:  Jiaxiang Yuan; Tao Liu; Xiefu Zhang; Yaqing Si; Yanwei Ye; Chunlin Zhao; Qun Wang; Xinsheng Shen
Journal:  J Gastrointest Surg       Date:  2015-06-18       Impact factor: 3.452

Review 5.  Interdisciplinary position statement on management of hyperglycemia in peri-operative and intensive care.

Authors:  Sukhminder Jit Singh Bajwa; Manash P Baruah; Sanjay Kalra; Mukul Chandra Kapoor
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2015 Apr-Jun

Review 6.  Effects of perioperative tight glycemic control on postoperative outcomes: a meta-analysis.

Authors:  Zhou-Qing Kang; Jia-Ling Huo; Xiao-Jie Zhai
Journal:  Endocr Connect       Date:  2018-12-01       Impact factor: 3.335

Review 7.  Postoperative tight glycemic control significantly reduces postoperative infection rates in patients undergoing surgery: a meta-analysis.

Authors:  Yuan-Yuan Wang; Shuang-Fei Hu; Hui-Min Ying; Long Chen; Hui-Li Li; Fang Tian; Zhen-Feng Zhou
Journal:  BMC Endocr Disord       Date:  2018-06-22       Impact factor: 2.763

8.  The Japan Society for Surgical Infection: guidelines for the prevention, detection, and management of gastroenterological surgical site infection, 2018.

Authors:  Hiroki Ohge; Toshihiko Mayumi; Seiji Haji; Yuichi Kitagawa; Masahiro Kobayashi; Motomu Kobayashi; Toru Mizuguchi; Yasuhiko Mohri; Fumie Sakamoto; Junzo Shimizu; Katsunori Suzuki; Motoi Uchino; Chizuru Yamashita; Masahiro Yoshida; Koichi Hirata; Yoshinobu Sumiyama; Shinya Kusachi
Journal:  Surg Today       Date:  2020-12-15       Impact factor: 2.549

9.  Intensive glucose control for critically ill patients: an updated meta-analysis.

Authors:  Yongli Fu; Yaowu Sun; Jiankun Zhang; Yu Cheng
Journal:  Endocr Connect       Date:  2018-12-01       Impact factor: 3.335

10.  Is intensive glucose control bad for critically ill patients? A systematic review and meta-analysis.

Authors:  Ren-Qi Yao; Chao Ren; Guo-Sheng Wu; Yi-Bing Zhu; Zhao-Fan Xia; Yong-Ming Yao
Journal:  Int J Biol Sci       Date:  2020-03-12       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.